



Roth Conference
March 8-11, 2015

Dr. Rob Crombie
Managing Director

Disclaimer and Safe Harbor

Certain statements made in this presentation are forward-looking statements within the meaning of the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on Prescient's current expectations, estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this presentation, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient or Prescient. (collectively, "Prescient" or the "Company") to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Investment Highlights


Novel Technology	2 small molecule drug candidates targeting key cancer pathways, AKT (PTX-200) and Ras (PTX-100)
Multiple Shots on Goal	5 clinical trials: 2 underway and 3 on track to initiate within 12 months
News Flow	Multiple milestone announcements and valuation inflexion points over next 12 to 18 months
Robust IP	Patents to 2030 granted in major jurisdictions
Proven Leadership & Management	Experienced team on board to aggressively drive product development
Highly Leveraged Resources	US-based team with trials underway at top cancer centers funded by US grants from National Cancer Institute and Department of Defense AU-based team backed by strong Govt support as “R&D Tax Incentive” covers Clinical & CMC costs
Significant Investment to Date	~US\$20M invested to date

Developing Two Novel Cancer Compounds

- **PTX 100 – Blocks Ras signalling pathway**
- **PTX 200 – Blocks AKT signalling pathway**
- **Both pathways mediate chemotherapy resistance**
- **Multi-pronged approach to breaking chemotherapy resistance**

Clinical Trials Recruiting & Planned for 2015

Targeting AKT & Ras Cancer Pathways



* Funded by
NCI support

* Funded by
DoD support

Market Opportunity - Prescient

- **Chemotherapy resistance**


- Primary cause of failure of existing chemotherapy treatments
- Critical unmet need for new agents

- **Prescient's oncology drug candidate development strategy**

- Developing therapies to overcome resistance by switching off Ras and AKT pathways
- Enable restoration of front line therapies such as cisplatin, taxol, bortezomib, etc.
- Both PTX-100 and PTX-200 trials designed with the potential for a “personalized” approach – enhancing drug development and treatment

PTX-200: Summary


- Activated AKT plays key role in many cancers including breast, ovarian, colorectal, prostate, pancreatic and hematologic cancers
- Strong interest in AKT as a drug target
- PTX-200 inhibits AKT pathway & overcomes resistance to chemotherapeutic agents
- PTX-200 causes cancer cells to die



PTX-200: Mechanism of Action

AKT is an ON/OFF switch that controls normal cell division


AKT is **ON** when phosphorylated and **OFF** when not



PTX-200: Mechanism of Action


Some cancer cells contain Akt that is always phosphorylated* stimulating cells to divide forever

Akt is **ON** when phosphorylated and **OFF** when not



PTX-200: Extensive Clinical Experience

- **Phase 1 programs Completed: H Lee Moffitt & MD Anderson**
 - Library screen identified PTX-200 as a potent AKT inhibitor
 - Evaluated in Acute Leukemia and Solid tumor clinical studies
 - PTX-200 shown to decrease pAKT levels in tumors
 - Acute Leukemia: Phase 1 study demonstrated 17 out of 32 patients had stable disease after one cycle of treatment
 - 3 patients with AML achieved >50% bone marrow blast reduction.
 - 1 patient with CMML had marked spleen reduction and a return to a normal white blood cell count



PTX-200: Ongoing Clinical Studies

- **Breast Cancer – PTX-200 plus Taxol in patients with metastatic and locally advanced breast cancer**
 - Recruiting at Albert Einstein College of Medicine Montefiore Medical Center
 - Funded by National Cancer Institute grant
 - Phase 1; 15 patients already dosed
 - Phase 2 to commence 1H 2015

- **Ovarian Cancer – PTX-200 plus Carboplatin in platinum resistant ovarian cancer**
 - Significant need for new products to treat platinum-resistant cancer
 - Recruiting at Lee Moffitt Cancer Center
 - Funded by US Department of Defense grant
 - Phase 1b; 6 patients already dosed
 - Phase 2 to commence 1H 2015



Dr Joseph Sparano,
Principal Investigator –
Montefiore Einstein Cancer Center




Dr Patricia Judson,
Principal Investigator – Center for
Women's Oncology Moffitt



PTX-200: Proposed Phase 1b/2 Acute Myeloid Leukemia Clinical Program

- **Phase 1b/2 PTX-200 plus cytarabine in refractory or relapsed acute leukemia**
 - Protocol in place; ready to initiate H1 2015
 - Refractory patients in combination with cytarabine
 - Phase 2 arm – 24 patients with AML in early 1st relapse (less than 6 months)
 - Target accrual completion - 24 months





Dr Jeffrey E Lancet MD,
Principal Investigator
Moffitt Cancer Center




PTX-100: Summary

- Small molecule inhibitor of the Ras signaling pathway
- Invented at Yale University and Moffitt Cancer Center
- Blocks important cancer growth enzyme geranylgeranyl transferase
- Phase 1 trials demonstrated it is well tolerated, patients achieved stable disease
- PTX-100 shown to reduce cancer stem cell population in animal models




PTX-100: Mechanism of Action

Ras and Ral are ON/OFF switches that control normal cell division





PTX-100: Mechanism of Action

Ral requires geranylgeranylation (GG) to cause cancer



PTX-100: Phase 1 Completed

Patients	13
Trial Centers	 INDIANA UNIVERSITY  Penn UNIVERSITY of PENNSYLVANIA
Patient Inclusion	Advanced solid tumors for which standard treatments failed – “refractory”
Methods	PTX-100 as a 30-min IV infusion on Days 1-5 every 21 days
Study Objectives	<ul style="list-style-type: none">• Determine dose limiting toxicity (DLT)• Assess safety, tolerability & pharmacokinetics• Observe clinical response & explore biomarkers
Summary	<ul style="list-style-type: none">• Well tolerated – nausea main adverse event• Elevation in Liver Function Test identified as the dose limiting toxicity• Stable disease achieved in 4 cancer patients

PTX-100: Planned Trials

Phase 1b/2 Multiple Myeloma

- High mortality rate, large unmet medical need
- Phase 1b dose escalation in >18 patients to determine safe & effective dose for Phase 2
- Phase 2 trial of PTX-100 in combination with Velcade™ in 36 patients
- To commence in 2H 2015



Phase 1b Breast Cancer

- High unmet medical need for advanced disease
- Phase 1b dose escalation in patients with metastatic breast cancer in combination with Docetaxel
- Design includes p27 diagnostic – Exclusive rights held by PTX
- To commence in 2H 2015



Robust Intellectual Property Portfolio

PTX-100

- Strong Composition of Matter patent covering “Piperazinone compounds as anti-tumor and anti-cancer agents & methods of treatment”
- Patent Life: 2025 with possibility to extend to 2030
- Methods of Use patent for “Inducing tumor regression, inhibiting tumor growth & inducing apoptosis in breast tumors with geranylgeranyltransferase inhibitors”
- Opportunities to establish new IP rights

PTX-200

- IP estate anchored by “foundational” patent issued Jan 2013
- Established PTX-200 as a targeted therapy by specifying cancer patients with AKT over-expression
- 9 granted and 7 pending applications in US
- Pending applications in EU, Canada, Japan, Hong Kong, Australia

Executive Management

Rob Crombie
Managing Director



- 18 years in private and public biotech in the UK and Australia
 - Significant business development track record of closing deals between biotechnology and pharma
- Formerly head of Melbourne operations at Arana Therapeutics
 - From start-up phase as EvoGenix through IPO to a \$318 million cash sale to Cephalon (Teva Pharmaceuticals)

Paul Hopper
Executive Director



- 20 years experience in international public company markets with a focus on life science and start-ups
- Chairman of Viralytics Ltd and Executive Chairman of Imugene Ltd
- Advisor at Los Angeles-based Cappello Group and Head of Life Sciences and Biotechnology Group

Board of Directors & Scientific Advisory Board

	Steve Engle <i>Non-Executive Chairman</i>	<ul style="list-style-type: none">• Former Chairman and CEO of US-listed XOMA (NASDAQ:XOMA) and La Jolla Pharmaceuticals (NASDAQ: LJPC)• Currently CEO of Averigon Consulting, an advisory firm to life science industry
	Dr. James Campbell <i>Non-Executive Director</i>	<ul style="list-style-type: none">• Previously CFO and Chief Operating Officer of Chemgenex• Non-Executive Director of Invion (ASX:IVX), BioProspect Limited (ASX:BPO) and Patrys Limited (ASX:PAB)
	Steve Yatomi-Clarke <i>Non-Executive Director</i>	<ul style="list-style-type: none">• Director of Corporate Finance at Patersons Securities specializing in healthcare and biotechnology• Collaborator on clinical trials conducted in Australia and the US in cancer immunotherapy field
	Professor Joseph Sparano	<ul style="list-style-type: none">• Professor of Medicine and Professor of Obstetrics, Gynecology and Women's Health at the Albert Einstein College of Medicine, New York• Associate Director for Clinical Research at the Einstein Cancer Center, NY
	Professor Douglas Joshua	<ul style="list-style-type: none">• Emeritus Professor of Hematology at the Sydney University Medical School• Consultant Hematologist, Royal Prince Alfred Hospital.• Member of the International Myeloma Foundation

Multiple Milestones Over Next 12-18 Months

		2014	2015	2016-17
PTX-200	Initiate Phase 1b (Ovarian) ²	✓		
PTX-200	Complete Phase 1b (Breast) ¹			
PTX-100	Reactivate Breast IND			
PTX-100	File IND for Multiple Myeloma			
PTX-200	Initiate Phase 2(Breast) ¹			
PTX-200	Complete Phase 1b (Ovarian)			
PTX-200	Open Acute Leukemia trial			
PTX-100	Open Multiple Myeloma Trial			
PTX-100	Open Breast Trial			
PTX-200	Initiate Phase 2 (Breast) ¹			
PTX-200	Initiate Phase 2 (Ovarian) ²			
PTX-100	Close Multiple Myeloma Trial			

1. Funded by National Cancer Institute RO1 Grant.

2. Funded by US Department of Defense Grant.

Financial Summary


Key Metrics

ASX Ticker	PTX
Share Price ¹	A\$0.11
Market Cap ¹	A\$5.5 million
Cash Position ²	A\$2.3 million
Total Issued Capital	52 million shares
Options	87 million @ A\$0.05
Top 20 Own	33%
Average Daily Turnover (3m)	224,453

1 - As of 7/3/2015

2- As of 27/2/2015

Shareholder Base



Market Caps of Oncology Companies at a Similar Stage

Company	Exchange	Lead Product Status	Number of Products	Market Cap \$ USD mm
Helix Biopharma	TSX:HBP	Phase 2	2	111
Coronado Biosciences	NASDAQ:CNDQ	Phase 2	2	123
VBL Therapeutics	NASDAQ:VBLT	Phase 2	2	73
Provectus Biopharmaceuticals	NYSE:PVCT	Phase 2	2	151
Benitec	ASX:BLT	Phase 1	3	73
Bionomics	ASX:BNO	Phase 2	6	166
Viralitics	ASX:VLA	Phase 2	platform	68

As of March 3rd 2015

Why Prescient?

Novel Technologies

Multiple Shots on Goal

News Flow

Robust IP

Proven Leadership & Management

Significant Investment to Date

Leveraging Resources



Contact

Dr. Rob Crombie

Managing Director

Robert.Crombie@PrescientTherapeutics.com

+61 439 361 331

